Gemcitabine and cisplatin are two drugs commonly used to treat biliary cancers (those of the bile duct and gallbladder), but despite this approach, many patients succumb to these illnesses. Researchers want to determine if adding an investigational drug called MEK162 to treatment with gemcitabine and cisplatin improves the effectiveness of therapy.
MEK162 works by inhibiting a protein called MEK1/2, which can fuel cancer cell growth. It is taken orally (by mouth). In this study, investigators want to determine the highest dose of MEK162 that can be given safely as initial therapy in patients with advanced bile duct and gallbladder cancers, and observe its preliminary effectiveness against these cancers.